Collins Stewart maintains a 'Sell' on Amylin Pharmaceuticals (AMLN); Bydureon Now Has 2% Market Share

Collins Stewart maintains a 'Sell' on Amylin Pharmaceuticals (NASDAQ: AMLN) price target of $12.00.

Collins analyst said, "This morning, IMS released GLP-1 weekly prescription numbers for the week ending Mar 2. Bydureon TRx for the week ending Mar 2 were 1,259, up 70% WoW (from 743 prev.). NRx were 1,264 (from 743 prev.), also up 70% WoW. In its third week of launch, Bydureon is tracking below Victoza's launch, in which Week 3 TRx were 1,465.

For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.

Shares of Amylin Pharmaceuticals closed at $15.79 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FI) PT Raised to $175 at TD Cowen
• UBS Reiterates Neutral Rating on Crane (CR)
• Halliburton (HAL) PT Raised to $52 at Wolfe Research